revive rx tirzepatide Therapy for Better Health Revive Rx | 503A Compounding

But here's the key where they act makes ALL the difference

It is estimated that 1030% of individuals with NAFLD can be complicated by NASH and approximately 20% of individuals with NASH will progress to cirrhosis, hepatocellular carcinoma and/or liver failure

10

Studies using dual-energy X-ray absorptiometry (DXA) demonstrate reductions in total fat mass up to 10.9 kg, with particular effectiveness in reducing visceral fatthe metabolically harmful abdominal fat strongly associated with cardiovascular and metabolic disease risk

Your input helps us make our services better

A patient on Wegovy 2.4 mg who starts tirzepatide at 10 mg rather than 2.5 mg would be introducing a novel molecule at a dose far higher than the tolerability data support for initiators [1][6]